Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027

Novo Nordisk used the American Diabetes Association congress in New Orleans to unveil a far-reaching strategic pivot that goes well beyond the current blockbuster Wegovy. Chief executive Mike Doustdar signalled the Danish drugmaker intends to become a force in longevity research and aesthetic medicine, with new data suggesting semaglutide can reduce the biological age of the heart and kidneys. The stock, however, remained stuck near its lows – a reflection of the gap between a bold long-term vision and an immediate pipeline timeline that stretches deep into 2027.

Clinical data presented at the conference offered genuine cause for optimism about the next generation of obesity and diabetes treatments. Zenagamtide, also referred to as Amycretin, delivered a 14.6% weight reduction over 36 weeks in a phase-2 trial involving 262 patients at the highest dose. HbA1c levels fell by as much as 1.71 percentage points. A phase-3 programme for type-2 diabetes is set to start in the second half of 2026. Meanwhile, the REIMAGINE-2 study for CagriSema – a combination of semaglutide and cagrilintide – enrolled roughly 2,700 participants and posted a 14.2% weight loss, compared with 10.2% for semaglutide alone. Yet the market’s enthusiasm was tempered by the expected timeline: regulatory approval for CagriSema in diabetes is not anticipated until late 2027 at the earliest.

Doustdar used the ADA stage to articulate a broader vision. Semaglutide, he argued, should eventually be seen as an agent against aging, not merely a weight-loss tool. Post-hoc analyses from the SELECT and STEP studies indicated a 48% lower rate of obstructive sleep apnoea and a 42% reduction in asthma events. The CEO added that the drug’s protective effects on the heart and kidneys – measured by protein-based aging clocks – appear independently of weight loss. When asked whether the company might invest in skincare or hair-loss treatments, his answer was a clear “yes,” underscoring a push into aesthetic medicine alongside the core metabolic franchise.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Despite this ambitious narrative, Novo Nordisk’s shares continue to trade under heavy pressure. At around €36.50, the stock sits nearly 48% below its 52-week high of €70.13 touched in June 2025. It has lost more than 18% since the start of the year. Analysts have trimmed their 2026 revenue forecast for the American launch of the Wegovy pill to roughly €1.8bn, about 5% below prior estimates. The oral version of Wegovy (25 mg) has nonetheless built up substantial momentum: since its US debut on 5 January 2026, it has surpassed three million prescriptions, with 80% of new patients having never taken a GLP-1 drug before.

In a parallel effort to shore up the share price, Novo Nordisk has been buying back its own equity. As of early June, the company had acquired nearly 18.8 million B-shares at an average price of DKK 264.32, spending approximately DKK 5bn under the current DKK 15bn repurchase programme. Whether this will stabilise the stock, however, depends on when investors stop counting the months until the next major approval.

The real test lies in the execution of a massively expanded platform. Novo Nordisk is no longer positioning itself as a pure-play GLP-1 specialist. Instead, it aims to become a broad-based company tackling age-related diseases and lifestyle medicine. The international roll-out of the Wegovy pill in the second half of 2026 – the United Arab Emirates has already given the green light – will provide the next big revenue driver for this transformation. For now, the market remains unconvinced, waiting for the pipeline to turn promise into profit.

Ad

Novo Nordisk Stock: New Analysis - 8 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69502342 |